TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include live… Read more
TaiwanJ Pharmaceuticals Co., Ltd. (6549) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.141x
Based on the latest financial reports, TaiwanJ Pharmaceuticals Co., Ltd. (6549) has a cash flow conversion efficiency ratio of -0.141x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-11.61 Million) by net assets (NT$82.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TaiwanJ Pharmaceuticals Co., Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how TaiwanJ Pharmaceuticals Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TaiwanJ Pharmaceuticals Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TaiwanJ Pharmaceuticals Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Superdong Fast Ferry Kien Giang JSC
VN:SKG
|
N/A |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
0.148x |
|
4C Group AB
ST:4C
|
0.019x |
|
Star Media Group Bhd
KLSE:6084
|
0.016x |
|
The Caldwell Partners International Inc
OTCQX:CWLPF
|
-0.018x |
|
Sievi Capital Plc
F:WE3
|
0.169x |
|
Orvana Minerals Corp
PINK:ORVMF
|
-0.021x |
|
NSE SA
PA:ALNSE
|
-0.027x |
Annual Cash Flow Conversion Efficiency for TaiwanJ Pharmaceuticals Co., Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of TaiwanJ Pharmaceuticals Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$95.05 Million | NT$-22.62 Million | -0.238x | -1840.47% |
| 2023-12-31 | NT$66.94 Million | NT$-821.00K | -0.012x | +95.83% |
| 2022-12-31 | NT$71.60 Million | NT$-21.07 Million | -0.294x | -378.83% |
| 2021-12-31 | NT$163.48 Million | NT$-10.05 Million | -0.061x | +73.81% |
| 2020-12-31 | NT$175.92 Million | NT$-41.28 Million | -0.235x | -311.12% |
| 2019-12-31 | NT$151.66 Million | NT$16.86 Million | 0.111x | -- |